Navigation Links
Federal Judge Rejects GlaxoSmithKline's Claims of Privilege
Date:12/10/2009

PHILADELPHIA, Dec. 10 /PRNewswire/ -- In a decision of importance to the case at hand and all cases involving claims of attorney-client or work product privilege, the Honorable Cynthia M. Rufe of the United States District Court for the Eastern District of Pennsylvania, in a decision of December 7, 2009, has ruled that GlaxoSmithKline (GSK), the manufacturer of the prescription diabetes medication Avandia, must produce dozens of documents that it withheld on claims of privilege.

The lawsuit alleges that GSK failed to warn consumers about the risks of Avandia, including that of heart attacks. The case has been assigned by the Panel on Multidistrict Litigation to Judge Rufe.

Judge Rufe's ruling comes on an appeal by GSK of a ruling by Special Discovery Master Jerome J. Shestack, Esquire.

Judge Rufe's opinion first outlines several overarching principles on the attorney-client privilege under Pennsylvania law and the federal work product doctrine, and then addresses the particular documents in question.

Her opinion notes, for example, that the "attorney-client privilege does not shield documents merely because they were transferred or routed through an attorney," and that "documents prepared by a corporation as part of efforts to ensure compliance with federal regulatory agencies or maintain a positive public image for its products, and not because of possible litigation, are not protected by [the] work-product doctrine."

Importantly, Judge Rufe rejects one of GSK's principal arguments: its interpretation of the "primary purpose" requirement of the attorney- client privilege. Pennsylvania law provides that in order to come within that privilege, the primary purpose of a document must be to secure or give legal advice. The documents in question included ones sent to a group of persons, only one (or more) of whom was an attorney. GSK argued that in determining whether the "primary purpose" requirement was met for those documents, the inquiry should be only to the purpose of sending the document to the attorney(s), rather than the primary purpose of the document as a whole. Judge Rufe finds that this interpretation has "no support" in cases applying Pennsylvania law, including the lead case on which GSK relied, Ford Motor Co. v. Kelly, 110 F.3d 954 (3d Cir. 1997), and that this interpretation is "inconsistent with the requirement that privileges must be narrowly construed."

Joseph F. Roda of RodaNast, P.C., Lancaster, PA, briefed and argued the motions on behalf of the plaintiffs. He was assisted by Jennifer S. Snyder, also of RodaNast, P.C. Lead Counsel for the plaintiffs are Vance Andrus of Andrus Boudreaux, PLC, Denver, CO; Bryan Aylstock of Aylstock, Witkin, Kreis & Overholtz, Pensacola, FL; and W. Mark Lanier of The Lanier Law Firm, PLLC, Houston, TX.

SOURCE RodaNast, P.C.


'/>"/>
SOURCE RodaNast, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot
4. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
5. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
6. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
7. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
8. Faced With Federal Prosecution, MountainView Agrees to Stop Harassment of RNs in Settlement With Labor Board
9. Malaria Experts Call on Federal Government to Increase Support for Research and Development
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to market ... and Demand Forecast to 2022 - Industry Insights by Slice ... Center and Others)" by P&S Market Research, the global ... 2015, and it is expected to grow at a CAGR ... slice type segment is expected to witness the faster growth, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... KANSAS CITY, Mo. , May 3, 2016 ... of Kansas Medical Center,s Institute for Advancing Medical ... develop and commercialize new drugs, diagnostics and medical ... organizations provides BioNovus Innovations with rights to license, ... "This partnership ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology ... food item donations for Food for Lane County, and to help support awareness for ... of the assembly was to create an exciting atmosphere for the kids at Riverbend ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, ... blood and service orders. Blood suppliers and their hospitals use BloodHub for ... serves 13,000 active users across 2,100 hospitals who use our platform to processes ...
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... “Less than ... Jeffers, Little City Executive Director. “As one of ten non-profit organizations to participate and ... Points of Light. The ultimate benefit is that for every $1 we invest in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... million in grants to identify, fund and implement ideas aimed at improving care ... Medicaid. , “Part of our vision for Trinity Health is to drive ...
(Date:5/4/2016)... Charlotte, NC (PRWEB) , ... May 04, 2016 ... ... platform for sleep wellness and sleep disorder management, today announced it has secured ... World Innovation Lab (WiL) and existing investors. The investment will be used by ...
Breaking Medicine News(10 mins):